Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis

Overview of attention for article published in Drug Design, Development and Therapy, October 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 1 news outlet

twitter: 3 X users

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 23 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

Emerging Trends That Challenge the Landscape of Care for Multiple Sclerosis: Stephen Krieger, MD

Neurology Live, 03 Oct 2023

WATCH TIME: 3 minutes “In MS, there's an emerging category of treatments called BTK inhibitors that are all in phase 3 trials…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.